Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

February 22, 2021February 22, 2021

Xpovio Open to Advanced Myeloma Patients Outside US via Access Program

News

People with advanced multiple myeloma and diffuse large B-cell lymphoma (DLBCL) will soon be able to access Xpovio (selinexor) outside the U.S. through a managed access program. This program, also known as ... Read more

January 18, 2021January 18, 2021

FDA Gives Orphan Drug Status to Potential Multiple Myeloma Immunotherapy

News

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Harpoon Therapeutics‘ investigational immunotherapy HPN217 as a possible treatment of multiple myeloma. The designation encourages the development of potential therapies ... Read more

January 4, 2021February 1, 2021

FDA Approves Xpovio Triple Combo for Previously Treated Myeloma

News

The U.S. Food and Drug Administration (FDA) has approved a triple combination of Xpovio (selinexor) plus Velcade (bortezomib) and low-dose dexamethasone for the treatment of people with multiple myeloma who ... Read more

December 9, 2020December 9, 2020

Xpovio Approval Sought for Myeloma Indications in 3 Asian Pacific Markets

News

Antengene is asking health authorities in Singapore, Australia, and Hong Kong to approve Xpovio (selinexor) for the treatment of multiple myeloma, the company announced in a press release. Specifically, the ... Read more

November 18, 2020November 18, 2020

Approval of Injection Darzalex Combo for Advanced Myeloma Sought in US, EU

News

Janssen is seeking to extend approval of its under-the-skin formulation of Darzalex (daratumumab) to include its use in combination with Pomalyst (pomalidomide) and dexamethasone to treat relapsed or refractory multiple myeloma patients who received at ... Read more

October 14, 2020October 14, 2020

Cytovia, Inserm Partnering on NK-based Immunotherapies for Myeloma

News

A recent collaboration between Cytovia Therapeutics and Inserm, the French National Institute of Health and Medical Research, aims to advance new immunotherapies against multiple myeloma based on natural killer cells. Cytovia ... Read more

September 21, 2020September 21, 2020

FDA Grants Fast Track Designation to ‘Off-the-shelf’ CAR T-cell Therapy

News

The U.S. Food and Drug Administration has granted fast track designation to PBCAR269A, Precision BioSciences‘ donor-derived CAR T-cell therapy for the treatment of relapsed or refractory multiple myeloma. Fast track status ... Read more

September 4, 2020September 4, 2020

Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Oncopeptide’s application seeking accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for people with relapsed or refractory multiple myeloma (RRMM). The new drug application ... Read more

September 2, 2020September 2, 2020

Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma

News

The first patient has been dosed in a Phase 1/2a trial investigating Precision BioSciences‘ new CAR T-cell therapy candidate, PBCAR269A, for people with relapsed or refractory multiple myeloma. The dose-escalation trial ... Read more

July 10, 2020July 10, 2020

FDA Accelerated Approval of Melflufen Sought for Hard-to-treat Myeloma Patients

News

Oncopeptides has submitted a new drug application to the U.S. Food and Drug Administration (FDA) requesting the accelerated approval of melflufen (melphalan flufenamide) plus dexamethasone for hard-to-treat patients with multiple myeloma. The ... Read more